Ignite Creation Date:
2024-05-06 @ 1:47 AM
Last Modification Date:
2024-10-26 @ 11:09 AM
Study NCT ID:
NCT01894789
Status:
COMPLETED
Last Update Posted:
2017-04-24
First Post:
2013-02-27
Brief Title:
Ticagrelor vs Clopidogrel Effect on MFR in CAD Population
Sponsor:
Ottawa Heart Institute Research Corporation
Organization:
Ottawa Heart Institute Research Corporation
Study Overview
Official Title:
ComPArison of the Effect of Ticagrelor Versus Clopidogrel on Myocardial Blood Flow MBF and Reserve MBFR Measured With Positron Emission TomograpHy PET in Patients With Coronary Artery Disease CAD The PATH Study
Status:
COMPLETED
Status Verified Date:
2017-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PATH
Brief Summary:
Ticagrelor is one of 3 anti-platelet medications used in patients with acute coronary syndrome ACS to prevent further clot formation and further ischemic damage to myocardial tissue Overall benefits of one drug over the other is neutral in this generally unstable population In pre-clinical trials ticagrelor showed secondary effects involving the release of adenosine to heart muscle where the demand for blood was increased due to a stress condition Blood flow was increased potentially preventing potential damage
This study will compare ticagrelor currently only approved for use in ACS patients against clopidogrel by measuring the myocardial blood flowMBF during stress to validate this phenomenon The effect on blood flow will be measurable by using two specific doses of adenosine as the pharmacologic stress and correlating with measurements of blood flow using positron emission tomography PET nuclear imaging
This study hypothesizes that the increase in MBF during intermediate dose adenosine infusion will be greater in ticagrelor treated subjects compared to clopidogrel treated subjects
This study will compare ticagrelor currently only approved for use in ACS patients against clopidogrel by measuring the myocardial blood flowMBF during stress to validate this phenomenon The effect on blood flow will be measurable by using two specific doses of adenosine as the pharmacologic stress and correlating with measurements of blood flow using positron emission tomography PET nuclear imaging
This study hypothesizes that the increase in MBF during intermediate dose adenosine infusion will be greater in ticagrelor treated subjects compared to clopidogrel treated subjects
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None